All In Biotech

Drug Trial Radar · NCT05113251

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 927 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

927

Actual

Start

Oct 25, 2021

Primary completion

Mar 12, 2025

Study completion Apr 30, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Nov 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.

Conditions

  • Breast Neoplasms
  • Breast Cancer
  • HER2-positive Early Breast Cancer

Interventions

  • Trastuzumab DeruxtecanDrug

    administered by intravenous infusion

  • PaclitaxelDrug

    administered by intravenous infusion

  • TrastuzumabDrug

    administered by intravenous infusion

  • PertuzumabDrug

    administered by intravenous infusion

  • DoxorubicinDrug

    administered by intravenous infusion

  • cyclophosphamideDrug

    administered by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Pathologic Complete Response (pCR).Time frame: Through to definitive surgery or discontinuation/withdrawal from study, up to a maximum of approximately 40 months from randomization to primary pCR DCO (12MAR2025)

Locations

145 sites in 18 countries. Site status is shown where the registry gives one.

  • Research Site

    Springdale, Arkansas

  • Research Site

    Beverly Hills, California

  • Research Site

    Glendale, California

  • Research Site

    Los Alamitos, California

  • Research Site

    Orange, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    Lexington, Kentucky

  • Research Site

    Louisville, Kentucky

  • Research Site

    Shreveport, Louisiana

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Las Vegas, Nevada

  • Research Site

    East Brunswick, New Jersey

  • Research Site

    Summit, New Jersey

  • Research Site

    Commack, New York

  • Research Site

    Durham, North Carolina

  • Research Site

    Greenville, South Carolina

  • Research Site

    Germantown, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Fort Worth, Texas

  • Research Site

    Ogden, Utah

  • Research Site

    Tacoma, Washington

  • Research Site

    Goiânia, Brazil

  • Research Site

    Ijuí, Brazil

  • Research Site

    Natal, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Panagyurishte, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Montreal, Canada

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Sherbrooke, Quebec, Canada

  • Research Site

    Beijing, China

  • Research Site

    Changsha, China

  • Research Site

    Changsha, China

Showing 40 of 145 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.